Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ring Guard is an over-the-counter topical combination antifungal and antibacterial cream, marketed primarily for the treatment of superficial dermatologic infections such as ringworm (tinea corporis), jock itch (tinea cruris), athlete’s foot (tinea pedis), and other mixed fungal and bacterial skin infections. It is formulated with the imidazole antifungal miconazole nitrate, which inhibits ergosterol synthesis in fungal cell membranes, and the aminoglycoside antibiotic neomycin sulfate, which binds bacterial 30S ribosomal subunits to block protein synthesis, together providing broad coverage against susceptible dermatophytes, yeasts, and bacteria. The product is used topically on affected skin to relieve symptoms such as itching, burning, redness, and irritation and is available in several branded variants (e.g., Plus, Advance) with the same core mechanism focused on local eradication of cutaneous fungal and bacterial pathogens.[1][3][4][7][8][9][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ring Guard.